Specific clinical features define HLA-A∗32:01–positive vancomycin drug reaction with eosinophilia and systemic symptoms: A multi-institution cross-sectional study
Year: 2025
Type: article
Authors: Matthew S. Krantz, Chantal Lemoine, Li Zhou, Andrew J. King, Daniela Kroshinsky, Elizabeth J. Phillips, Kimberly G. Blumenthal
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,000
Funders: Foundation of the American College of Allergy, Asthma & Immunology, Servier, Esperion Therapeutics, National Institutes of Health, Agency for Healthcare Research and Quality, American Academy of Allergy, Asthma and Immunology Foundation, Medical Research Council, National Health and Medical Research Council, National Human Genome Research Institute, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases
Awards: G1604131386, G2247833358, G2508017656, G265873141, G3133312458, Clinical Informatics to Advance Epidemiology and Pharmacogenetics of Serious Cutaneous Adverse Drug Reactions, Improving Prediction of Drug Action, G3702547411, G5171394123, G547490359, G5816948237, Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors, G6771029017, G7228442441, G7397460205, G8679115964, G8754570762, G9000018720, A Translational Bioinformatics Approach for Phenotyping and Genetic Risk of Severe Cutaneous Adverse Drug Reactions, Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study), NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, Optimizing the diagnostic approach to cephalosporin allergy testing (DACAT Trial)
OpenAlex ID: W4410593915